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Abstract
Aims: Proline-rich tyrosine kinase 2 (Pyk2), a non-receptor tyrosine kinase of the focal adhesion kinase (FAK) family, is up-
regulated in more than 60% of the tumors of hepatocellular carcinoma (HCC) patients. Forced overexpression of Pyk2 can
promote the proliferation and invasion of HCC cells. In this study, we aimed to explore the underlying molecular mechanism
of Pyk2-mediated cell migration of HCC cells.
Methodology/Principal Findings: We demonstrated that Pyk2 transformed the epithelial HCC cell line Hep3B into a
mesenchymal phenotype via the induction of epithelial to mesenchymal transition (EMT), signified by the up-regulation of
membrane ruffle formation, activation of Rac/Rho GTPases, down-regulation of epithelial genes E-cadherin and cytokeratin
as well as promotion of cell motility in presence of lysophosphatidic acid (LPA). Suppression of Pyk2 by overexpression of
dominant negative PRNK domain in the metastatic HCC cell line MHCC97L transformed its fibroblastoid phenotype to an
epithelial phenotype with up-regulation of epithelial genes, down-regulation of mesenchymal genes N-cadherin and
STAT5b, and reduction of LPA-induced membrane ruffle formation and cell motility. Moreover, overexpression of Pyk2 in
Hep3B cells promoted the phosphorylation and localization of mesenchymal gene Hic-5 onto cell membrane while
suppression of Pyk2 in MHCC97L cells attenuated its phosphorylation and localization.
Conclusion: These data provided new evidence of the underlying mechanism of Pyk2 in controlling cell motility of HCC cells
through regulation of genes associated with EMT.
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Introduction
Hepatocellular carcinoma (HCC) is the primary malignancy of
the liver. It is fifth in popularity and third in cancer-related deaths
worldwide [1]. Prognosis and treatment of HCC remains
unsatisfactory due to tumor recurrence, metastasis of the primary
tumor and poor therapeutic response to chemotherapy and
radiotherapy [2,3]. Metastasis is not only a complex process but
also the major cause of cancer-related deaths [4]. Transformation
of cells to a fibroblastic phenotype is important for the cancer cells
to successfully metastasize [5]. Several lines of evidences suggested
that the induction of epithelial to mesenchymal transition (EMT)
plays an important role in cancer cell transformation [6,7]. It
contributes significantly to metazoan embryogenesis and patho-
genesis such as tissue fibrosis and cancer progression [8]. On the
other hand, the process of mesenchymal to epithelial transition
(MET) may promote the growth of the metastatic cancer cells in
secondary sites [9]. The critical hallmarks of EMT include the
down-regulation of E-cadherin which is considered to be a tumor
suppressor gene [10], activation of Rho small GTPases such as
Rac1/RhoA which may increase cell motility by up-regulating
actin turnover and formation of focal adhesion [11], cytoskeletal
rearrangement and nuclear translocation of several transcription
factors such as Snail and Twist [12,13]. Understanding the
mechanism of HCC cell migration and metastasis may have great
value to develop effective diagnostic and therapeutic strategies for
treatment of HCC patients.
Proline-rich tyrosine kinase 2 (Pyk2) is a non-receptor tyrosine
kinase of the focal adhesion kinase (FAK) family. Our previous
study had shown that up-regulation of Pyk2 in tumor tissues of
HCC patients is significantly associated to poor prognosis [14].
Moreover, forced overexpression of Pyk2 in HCC cells promotes
cell proliferation, invasion and migration via the activation of the
c-Src and ERK/MAPK pathways which can be attenuated by
forced overexpression of its C-terminal non-kinase region
(PRNK)[15]. Furthermore, Pyk2 up-regulates the formation of
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[15]. However, the underlying mechanism of Pyk2 on regulation
of cell transformation and motility of HCC cells is poorly
understood. Recently, some of the signaling molecules associated
with Pyk2 (Hic-5 and STAT5b) have been reported to promote
EMT [16,17]. Therefore, it is valuable to investigate the effect of
Pyk2 on regulating these molecular in the process of cell
transformation of HCC cells.
Hydrogen peroxide inducible clone-5 (Hic-5) is a 55 kDa
protein that serves as an adaptor protein in focal adhesion and
possesses the ability to translocate to the nucleus, where it acts as a
transcription factor [18]. It maintains the general structure of
paxillin with 4 N-terminal LD motifs and 4 C-terminal LIM
domains [19,20]. The LIM domain of Hic-5 is able to bind with
DNA fragments in a zinc-finger-dependent manner in vitro,
suggesting its possible role as a transcription factor [21]. Pyk2
can physically interact with Hic-5 and subsequently phosphorylate
Hic-5 [22]. It has been reported that activated Pyk2 phosphor-
ylates Hic-5 at tyrosine residue 60 resulting in up-regulation of
LPA-mediated cell migration and the induction of EMT through a
RhoA/ROCK-dependent pathway [17,23,24]. So far the inter-
action between Pyk2 and Hic-5 in HCC is still unknown.
STAT5b belongs to the Signal Transducers and Activators of
Transcription (STAT) family which are activated by cytokines and
transcription factors via its dimerization and nuclear translocation.
They are involved in a variety of cell processes including cell
proliferation, cells survival and differentiation [25,26,27]. STAT5b
has been reported to promote EMT in HCC by the transforma-
tion of HCC cells into an aggressive phenotype. It has been shown
that the activation of STAT5b is closely associated with the X
protein of the Hepatitis B virus [16].
In this study, we hypothesize that Pyk2 transformed HCC cells
to a fibroblastoid phenotype through regulation of genes
associated with EMT. To validate the hypothesis, Hep3B cells
were stably overexpressed with full length Pyk2 and MHCC97L
cells were stably transfected with PRNK to suppress the Pyk2
activation. The gene expression profiles associated with EMT
(Hic-5, STAT5b, E-cadherin, Twist, N-cadherin, fibronectin and
Rho GTP-binding proteins) were investigated.
Materials and Methods
Reagents, plasmids and antibodies
Platelet derived growth factor-BB (PDGF-BB) was purchased
from Calbiochem (Darmstadt, Germany). Lysophosphatidic acid
(LPA) was purchased from Sigma (St. Louis, MO, USA). Plasmids
pCDNA3-Pyk2 and pCDNA3-PRNK were gifts from Dr. Joseph
Loftus, Mayo Clinic Scottsdale, USA. pCDNA 3.1 (+) vector was
purchased from Invitrogen (Carlsbad, CA). Anti-E-cadherin, anti-
N-cadherin, anti-Twist and Anti-phosphotyrosine monoclonal
antibodies were purchased from Cell Signaling (Danvers, MA,
USA). Monoclonal antibodies against cytokeratin (AE1/AE3) was
purchased from DAKO (Glostrup, Denmark). Anti-STAT5b and
anti-fibronectin antibodies were purchased from Santa Cruz
(Santa Cruz, CA, USA). Anti-Hic-5 and anti-Pyk2 monoclonal
antibodies were purchased from BD Transduction Laboratory
(San Jose, CA, USA). Alexa fluor 488 goat anti-rabbit IgG and
goat anti-mouse IgG were purchased from Molecular Probes
(Carlsbad, CA, USA).
Cell culture, transfection and stable cell lines
Human HCC cell line Hep3B was purchased from the
American Type Culture Collection (Manassas, VA, USA) and
grown in DMEM medium containing 10% FBS, 2 mM L-
glutamine, and 100 units/ml streptomycin (Life technologies,
Carlsbad, CA, USA). Human metastatic HCC cell line
MHCC97L was a gift from Prof. Z.Y. Tang, Fudan University,
Shanghai, China. Stable transfectants MHCC97L-vector and
MHCC97L-PRNK has been reported previously. Hep3B cells
were stably transfected with full length Pyk2 or PCDNA 3.1 (+)
empty vector and maintained in DMEM medium supplemented
with 300 mg/ml G418 as described previously [15]. The
expressions of Pyk2 in the stable clones were confirmed by
Western blotting. One clone with the highest expression of Pyk2
was selected for further study.
Scanning electron microscopy (SEM)
Cells were seeded in 13-mm glass dishes and maintained in
serum-free DMEM medium supplemented with 10% FBS and
antibiotics G 418 (0.6 mg/ml for Hep3B cells and 0.2 mg/ml
for MHCC97L cells). To study the effects of Rho small GTPases
activation on cell transformation, the cells were further treated
with PDGF-BB (10 ng/ml) or LPA (1 mg/ml) for 10 minutes
before cell fixation. Cells were fixed with 2.5% glutaraldehyde
in 0.1 M sodium cacodylate-HCL buffer, pH 7.4, quenched
with 0.1 M sucrose/cacodylate solution and washed in caco-
dylate buffer. The samples were then post-fixed with 1% OsO4
in cacodylate buffer. After a cacodylate buffer wash, samples
were dehydrated through a graded series of ethanol washes,
followed by critical point drying using a Bal-Tec CPD 030 (Bal-
Tec AG, Liechtenstein). The samples were sputter-coated with a
thin layer of gold (Bal-Tec SCD005 Sputter Coater) and
visualized using a Leica Cambridge Stereoscan 440 SEM at an
accelerating voltage of 12 kV. Each experiment was repeated
for 3 times.
Activation assays for Rac1 and RhoA
Rac and RhoA activation assays were purchased from
Cytoskeleton (Denver, CO, USA). Hep3B transfectants were
serum-starved overnight prior to experiment. Cells were treated
with PDGF-BB (10 ng/ml) or LPA (1 mg/ml) for 5 minutes and
were then lysed with lysis buffer. Rac1 and RhoA pull-down assays
were performed according to manufacturer’s protocol.
Migration assay
Cells were trypsinized, counted and resuspended in serum free
DMEM medium. Around 50,000 cells were seeded on the upper
side of the migration chamber (BD, San Jose, CA, USA) with the
lower chamber supplemented with serum free DMEM medium or
with LPA (1 mg/ml). After 36 hrs cells that had penetrated
through the chamber were fixed and counted.
Immunofluorescence staining
The protocol for immunofluorescent staining has been reported
previously [15]. Briefly, cells were fixed and stained with anti-E-
cadherin, anti-Hic-5 and anti-STAT5b antibodies. The cells were
then labeled with alexa fluor 488 goat anti-rabbit IgG or goat anti-
mouse IgG and counter-stained with DAPI at 37
oC.
Immunoprecipitation and Western blotting
Immunoprecipitation was performed on whole-cell lysates using
antibodies against Hic-5 and phosphotyrosine. The cells were
serum starved for 24 hours before stimulation with LPA for 20
minutes. Cell lysates were then incubated with anti-Hic-5 antibody
for 4 hours at 4
oC. Immunoprecipitates were washed twice in ice-
cold lysis buffer. Immunoblotting was carried out as previously
reported [15].
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All data were expressed as mean 6 SD. Difference between
groups were calculated by one-way ANOVA analysis. A p,0.05
was considered statistically significant. Unless stated, all experi-
ments were repeated three times. Calculations were performed by
using the SPSS computer software version 12 (SPSS, Chicago, IL).
Results
Pyk2 promoted formation of membrane ruffles
Forced overexpression of Pyk2 in the non-metastatic HCC cell
line Hep3B (Hep3B-Pyk2 cells) enhanced the formation of
lamellipodia and membrane ruffles upon stimulation by PDGF-
BB or LPA compared to control Hep3B-vector cells (Fig. 1A).
Suppression of Pyk2, by overexpression of PRNK domain, in the
metastatic MHCC97L cells (MHCC97L-PRNK cells) reduced the
formation of membrane ruffles, as compared to the MHCC97L-
vector control (Fig. 1B) in presence of PDGF-BB or LPA.
Migration assay demonstrated that Hep3B-Pyk2 exhibited a
significant increase of LPA-induced migration than Hep3B-vector
(p,0.05, Fig. 1C). Suppression of Pyk2 activation by PRNK
significantly down-regulated the cell migration in MHCC97L-
PRNK cells as compared to the vector control (p,0.05, Fig. 1C).
To elucidate the contributing mechanisms to the increase of
membrane ruffles formation in Hep3B-Pyk2 cells, Rac1 and RhoA
pull-down assays were performed to study the effects of Pyk2 on
LPA-induced activation of Rac1 and RhoA. Significant up-
regulation of activated forms and baseline levels of Rac1 and
RhoA were found in Hep3B-Pyk2 cells compared to Hep3B-
vector cells (Fig. 1D). For MHCC97L cells, no activated Rac1 and
RhoA was detected in their cell lysates due to low baseline levels of
Rac1 and RhoA (data not shown).
Pyk2 down-regulated the expression of E-cadherin and
cytokeratin
The effects of overexpression of Pyk2 on the regulation of
epithelial genes E-cadherin and cytokeratin were investigated.
Result from immunofluorescent staining showed that Hep3B-Pyk2
cells had lower level of E-cadherin expression and localization on
the cell membrane as compared to the Hep3B-vector cells
(Fig. 2A). Weak positive staining (green) was present in the
Figure 1. Pyk2 promoted cell motility of HCC cells. (A) Overexpression of Pyk2 in Hep3B cells enhanced the formation of membrane ruffles
while (B) suppression of Pyk2 in MHCC97L cells reduced the formation of membrane ruffles under the stimulation of PDGF and LPA. White arrows
indicate the presence of membrane ruffles. (C) Effects of Pyk2 on cell migration of Hep3B and MHCC97L cells in presence of LPA. *, P,0.05. (D) The
effect of over-expression of Pyk2 on the activation of Rac1 and RhoA in Hep3B cells by Rac1 and RhoA pull-down assays. Total Rac1 and RhoA were
used as loading controls.
doi:10.1371/journal.pone.0018878.g001
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cadherin. Western blot analysis showed that the expression levels
of E-cadherin and cytokeratin were lower in Hep3B-Pyk2 cells
compared with that in Hep3B-vector cells (Fig. 2B). In
MHCC97L-vector cells with high baseline level of Pyk2, E-
cadherin expression was almost absent in the cytoplasm of the cells
(Fig. 2C). Transfection of PRNK in MHCC97L cells significantly
restored the expression of E-cadherin at cytoplasm and on cell
membranes (green, Fig. 2C). Western blot analysis showed that
suppression of Pyk2 activation by PRNK restored the expression
of E-cadherin and cytokeratin (Fig. 2D) in MHCC97L-PRNK
cells. These results confirmed the role of Pyk2 on down-regulation
of epithelial genes E-cadherin and cytokeratin.
Pyk2 activated Hic-5 and its focal adhesion localization
Inmmunofluorescent staining demonstrated that Hic-5 was
predominantly present in the cytoplasm and the cell membrane of
the Hep3B-vector cells in a dispersed pattern (Fig. 3A). Overex-
pression of Pyk2 promoted the membrane localization of Hic-5 in
Hep3B-Pyk2 cells. Interestingly, more positive Hic-5 signals were
present on the membrane and the peri-nuclear region in the
Hep3B-Pyk2 cells (Fig. 3A). To further confirm the up-regulation
of phosphorylated Hic-5 by Pyk2 overexpression, immunoprecip-
itation was performed to determine the presence of phosphory-
lated Hic-5 in cultured cells. The level of phosphorylated Hic-5
was up-regulated in Hep3B-Pyk2 cells, as compared to the Hep3B-
vector control (Fig. 3B). In MHCC97L cells, Hic-5 was frequently
localized on the membrane region as shown by the strong green
positive staining by IF (Fig. 3C). Suppression of Pyk2 activation in
MHCC97L-PRNK cells significantly down-regulated the mem-
brane localization of Hic-5 (Fig. 3C). Moreover, Western blot
result showed that suppression of Pyk2 resulted in the down-
regulation of phosphorylated Hic-5 in MHCC97L-PRNK cells
(Fig. 3D). These results confirmed the positive correlation between
the expression of Pyk2 and the degree of phosphorylation and
membrane localization of mesenchymal gene Hic-5 inside the cell.
PRNK down-regulated the expression and activation of
STAT5b
In Hep3B-vector cells with low endogenous expression of Pyk2,
green positive immunofluorescent staining of STAT5b was
localized in the nuclear region of the cells, indicating its activation.
Overexpression of Pyk2 did not significantly enhance the
activation of STAT5b because of its intrinsic activation in the
vector control (Fig. 4A). Western blot analysis showed that
overexpression of Pyk2 in Hep3B did not up-regulate the
expression of mesenchymal genes including STAT5b and Twist
(Fig. 4B). For MHCC97L-vector cells, STAT5b was predomi-
nantly localized at the nucleus. Activated dimerized STAT5b, was
present in the nucleus (green; Fig. 4C). Suppression of Pyk2 in
MHCC97L-PRNK cells resulted in a loss of nuclear staining of
STAT5b. Positive staining of STAT5b was observed in the peri-
nuclear region and the cytoplasm, but not in the nucleus (Fig. 4C).
Western blot analysis confirmed the down-regulation of STAT5b
Figure 2. Effects of Pyk2 on epithelial genes cytokeratin and E-cadherin. (A) Effects of Pyk2 over-expression on the localization of E-cadherin
in Hep3B cells. Positive staining of E-cadherin (green, white arrow) was present in the cytoplasm of the transfectants. (B) Over-expression of Pyk2
down-regulated the expression of cytokeratin and E-cadherin in Hep3B cells as shown by Western Blotting. (C) Forced expression of PRNK in
MHCC97L cells restored the expression of E-cadherin (green, white arrow) on the cell membrane and cytoplasm. (D) The expression of E-cadherin and
cytokeratin was increased upon suppression of Pyk2 in MHCC97L cells.
doi:10.1371/journal.pone.0018878.g002
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MHCC97L-vector cells (Fig. 4D). In MHCC97L cells, suppression
of Pyk2 activation by PRNK resulted in down-regulation of other
mesenchymal genes such as Twist, N-cadherin and fibronectin
(Fig. 4D).
Discussion
We previously demonstrated that the focal adhesion localization
is a major determinant for Pyk2 to carry out its function in HCC
cells [15]. In this study, the role and underlying molecular
mechanism of Pyk2 on transformation of HCC cells to undergo
EMT were investigated. Forced overexpression of Pyk2 in Hep3B
cells transformed the cells from an epithelial phenotype to a
migratory phenotype which is commonly acquired by cancer cells
to induce EMT leading to the increase of metastatic potential [28].
Enhanced formation of membrane ruffles and migration ability in
Pyk2-overexpressing Hep3B cells suggested the promoting effect of
Pyk2 on cell motility of HCC cells. Increased activation of Rac1/
RhoA in Hep3B-Pyk2 cells indicated that Pyk2 might promote cell
motility of HCC cells via regulation of Rac1/RhoA activity.
Suppression of Pyk2 in a metastatic HCC cell line MHCC97L
showing a repression of EMT and cell migratory ability of the cells
also indicated the importance of Pyk2 in regulation of cell motility
of HCC cells.
The constitutive expression of E-cadherin in both normal and
cancer cells may help to maintain adherence junctions and
subsequently decrease the cell’s capacity to invade or migrate
through the extracellular matrix [29,30]. E-cadherin is frequently
down-regulated during tumor progression. Loss of E-cadherin is
associated with increased tumorigenecity and metastasis of cancer
cells, providing a close correlation between metastasis and EMT
[31]. Down-regulation of E-cadherin is usually coupled with an
up-regulation of N-cadherin [32]. In this study, overexpression of
Pyk2 in Hep3B cells resulted in a down-regulation of E-cadherin
expression while suppression of Pyk2 by PRNK in MHCC97L
cells significantly up-regulated the expression of E-cadherin,
suggesting the important mechanism of Pyk2 on the regulation
of adhesiveness of HCC cell via regulation of E-cadherin
expression.
The transcription factor, Hic-5, plays important roles in
tumorigenesis and metastasis of human cancers including prostate
cancer [33] and breast cancer [34]. Hic-5 is also a crucial EMT
regulator of cancer cells [20,24]. Our results demonstrated that
overexpression of Pyk2 in Hep3B cells up-regulated the activation
of Hic-5 and its focal adhesion localization. Moreover, suppression
of Pyk2 activation in MHCC97L cells down-regulated the
membrane localization of Hic-5. Hic-5 is a Pyk2-binding protein
which is phosphorylated by Pyk2 at tyrosine residue 60 upon
physical interaction [22,23]. Given the role of Hic-5 on cell
Figure 3. Effects of Pyk2 on the phosphorylation and activation of Hic-5. (A) Pyk2 over-expression promoted the membrane localization of
Hic-5. Positive staining of Hic-5 (green, white arrow) was up-regulated in Pyk2 transfected Hep3B cells. (B) Effect of Pyk2 over-expression on the
phosphorylation of Hic-5 in Hep3B cells. (C) Suppression of Pyk2 by PRNK down-regulated the localization of Hic-5 (green, white arrow) on cell
membrane and (D) level of activated Hic-5 in MHCC97L cells.
doi:10.1371/journal.pone.0018878.g003
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be one of contributing factors to the Pyk2-mediated cell
transformation in HCC. STAT5b and Twist have been reported
to promote aggressiveness and EMT of cancer cells in HCC
[16,35]. In this study, we demonstrated that Pyk2 also regulated
the expression of STAT5b and Twist in HCC cells, suggesting a
multiple regulatory roles of Pyk2 on EMT associated genes.
In this study, forced overexpression of Pyk2 in epithelial cancer
cell line Hep3B up-regulated the mesenchymal gene expression.
However, some of the mesenchymal genes were not up-regulated
in this study. This may be explained by the partial mesenchymal
characteristics of the Hep3B cells, which resulted in an
incomplete induction of EMT by Pyk2. In contrast, suppression
of Pyk2 activation in MHCC97L cells resulted in the down-
regulation of the expression a series of mesenchymal genes
including STAT5b, Twist, N-cadherin and fibroectin. These
results showed that Pyk2 regulated the expression of mesenchy-
mal genes and promoted the migratory characteristics of HCC
cells which can be attenuated by the forced expression of PRNK
to suppress Pyk2 activation. For cells with a mesenchymal
phenotype (MHCC97L cells), transfection of PRNK successfully
transformed the cells to an epithelial phenotype, with the down-
regulation of mesenchymal gene expression and up-regulation of
epithelial gene expression. E-cadherin was up-regulated with the
down-regulation of N-cadherin. The results showed that
suppression of Pyk2 by PRNK transformed the cells from a
mesenchymal phenotype, to an epithelial phenotype, by under-
going mesenchymal to epithelial transition (MET). These results
confirmed the involvement of Pyk2 in the regulation of EMT of
HCC cells.
Both EMT and MET are important processes in cancer
progression. The induction of EMT in cancer cells may enhance
their cell motility and invasiveness so that to facilitate the
development of metastasis [13,36]. Subsequently, circulating
tumor cells must undergo MET to initiate growth in a secondary
site [37]. Failure of MET induction in bladder cancer cells resulted
in micrometastasis, instead of secondary tumors, as shown by
experimental models [9]. Novel therapeutic strategies targeting the
MET process could be made to inhibit the development of cancer
metastasis by preventing secondary tumor formation. In this study,
we had shown that the process of both EMT and MET are
regulated by the alternation of Pyk2 activation. Overexpression of
Pyk2 in Hep3B cells resulted in the induction of EMT. On the
other hand, transfection of PRNK in MHCC97L cells resulted in
the induction of MET, suggesting that prevention of focal
adhesion by targeting of Pyk2 may transform HCC cells from a
mesenchymal phenotype to an epithelial phenotype. However, its
underlying mechanism is still unclear and thus considered to be
worthwhile for further study. Our previous study also demon-
strated that the suppression of Pyk2 by PRNK domain in
MHCC97L cells can suppress in vivo intrahepatic tumor growth
and venous invasion as well as extrahepatic lung metastasis [15].
Together, our data suggested the possible role of Pyk2 in the
regulation of EMT, MET and metastasis in HCC cells.
Our study demonstrated the important role of Pyk2 on
controlling cell motility of HCC cells through regulation of genes
Figure 4. Effects of Pyk2 on the activation of STAT5b. (A) Pyk2 over-expression did not increase activation of STAT5b in Hep3B cells (green,
white arrow). (B) Western blot analyses of protein level of phosphorylated STAT5b and Twist between Hep3B-vector and Hep3B-Pyk2 cells. (C)
Suppression of Pyk2 down-regulated the nuclear localization of STAT5b (green, white arrow) in MHCC97L cells. (D) Suppression of Pyk2 down-
regulated the phosphorylated STAT5b and other mesenchymal genes including Twist, N-cadherin and fibronectin analyzed by Western blot.
doi:10.1371/journal.pone.0018878.g004
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Targeting of Pyk2 should be a promising therapeutic strategy to
reduce HCC metastasis.
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